Marinus Pharmaceuticals’ (MRNS) “Overweight” Rating Reiterated at Cantor Fitzgerald

by · The Cerbat Gem

Cantor Fitzgerald restated their overweight rating on shares of Marinus Pharmaceuticals (NASDAQ:MRNS – Free Report) in a report released on Tuesday morning, Benzinga reports. Cantor Fitzgerald currently has a $13.00 target price on the biopharmaceutical company’s stock.

Several other equities analysts have also recently issued reports on the company. StockNews.com raised Marinus Pharmaceuticals from a sell rating to a hold rating in a report on Wednesday, September 18th. HC Wainwright restated a buy rating and issued a $11.00 price objective on shares of Marinus Pharmaceuticals in a research report on Wednesday, August 14th. LADENBURG THALM/SH SH lowered shares of Marinus Pharmaceuticals from a buy rating to a neutral rating in a report on Wednesday, August 14th. Truist Financial reissued a buy rating and set a $10.00 price target on shares of Marinus Pharmaceuticals in a report on Tuesday, June 18th. Finally, JMP Securities reaffirmed a market outperform rating and issued a $10.00 price objective on shares of Marinus Pharmaceuticals in a report on Monday. One analyst has rated the stock with a sell rating, three have assigned a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of Hold and a consensus target price of $8.83.

View Our Latest Report on Marinus Pharmaceuticals

Marinus Pharmaceuticals Price Performance

Shares of NASDAQ:MRNS opened at $1.73 on Tuesday. Marinus Pharmaceuticals has a twelve month low of $1.05 and a twelve month high of $11.26. The company has a current ratio of 2.28, a quick ratio of 2.15 and a debt-to-equity ratio of 5.68. The company has a market cap of $95.04 million, a PE ratio of -0.66 and a beta of 1.13. The company’s 50 day moving average is $1.40 and its 200 day moving average is $2.67.

Marinus Pharmaceuticals (NASDAQ:MRNS – Get Free Report) last issued its earnings results on Tuesday, August 13th. The biopharmaceutical company reported ($0.60) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.59) by ($0.01). The business had revenue of $8.06 million for the quarter, compared to analysts’ expectations of $9.05 million. Marinus Pharmaceuticals had a negative return on equity of 7,831.35% and a negative net margin of 493.14%. During the same period last year, the business earned ($0.61) EPS. On average, sell-side analysts forecast that Marinus Pharmaceuticals will post -1.88 EPS for the current year.

Hedge Funds Weigh In On Marinus Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in MRNS. Avoro Capital Advisors LLC increased its stake in shares of Marinus Pharmaceuticals by 31.4% during the first quarter. Avoro Capital Advisors LLC now owns 4,140,607 shares of the biopharmaceutical company’s stock worth $37,431,000 after purchasing an additional 990,607 shares in the last quarter. Acadian Asset Management LLC purchased a new stake in Marinus Pharmaceuticals during the 2nd quarter worth approximately $813,000. Renaissance Technologies LLC purchased a new position in shares of Marinus Pharmaceuticals in the second quarter valued at approximately $727,000. Superstring Capital Management LP purchased a new position in shares of Marinus Pharmaceuticals in the fourth quarter valued at approximately $5,027,000. Finally, XTX Topco Ltd purchased a new stake in shares of Marinus Pharmaceuticals during the second quarter worth approximately $232,000. 98.80% of the stock is owned by hedge funds and other institutional investors.

Marinus Pharmaceuticals Company Profile

(Get Free Report)

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.

See Also